-
Mashup Score: 21Enhanced Molecular Response in Myeloproliferative Neoplasms with Complete JAK2V617F Inhibition - 2 day(s) ago
Summary:. Dunbar, Bowman, and colleagues present here a novel genetic mouse model with inducible and reversible expression of the JAK2V617F mutation in the endogenous locus. Results from this study clearly demonstrate an absolute requirement for myeloproliferative neoplasm–initiating cells for this mutation in their survival and imply that more efficacious inhibitors could be curative for these patients even in the setting of additional cooperating mutations.See related article by Dunbar et al., p. 737 (8).
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Lucia Masarova, MD, PhD, elaborated on the latest updates across myeloproliferative neoplasms, focusing on significant studies and emerging therapeutic approaches.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Monitoring and Managing Anemia in Patients on Ruxolitinib - 7 day(s) ago
Dr. Bose shares his perspective on how he monitors and manages anemia for patients on ruxolitinib, including when he would consider dose reduction or transfusion.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Efficacy and Safety of JAK Inhibitors - 8 day(s) ago
Dr. Bose reviews the efficacy and safety findings from various studies on JAK inhibitors, including JAKARTA, PERSIST-1, PERSIST-2, SIMPLIFY-1 & 2, and MOMENTUM, and how these data inform his treatment choices.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10Factors in Selecting Initial PV Therapy - 9 day(s) ago
Dr. Kuykendall explains the factors he considers when deciding on initial therapy for advanced PV patients, including comorbidities, individual patient factors like age and symptoms, and weighing the risks and benefits of different treatment options.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 137Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management - 15 day(s) ago
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34Chernobyl and Biology: Dual Degree Prompts Alumni Award Winner to Pivot | School of Molecular & Cellular Biology | UIUC - 20 day(s) ago
Congratulations to Dr. Mesa, a 2024 College of Liberal Arts & Sciences Distinguished Alumni Award Recipient!
Source: mcb.illinois.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Navigating Emerging Therapies in Myelofibrosis Treatment - 24 day(s) ago
In an interview, Raajit K. Rampal, MD, PhD, delved into the dynamic landscape of myelofibrosis therapy, highlighting treatment options beyond JAK inhibition.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Gut Microbiota Differs in Patients With MPNs - 28 day(s) ago
Patients with MPNs who are JAK2V617F- and CALR-positive had different bacterial compositions compared with people without MPNs, research found.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 41
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
It was a great pleasure writing this spotlight article with @challenlab. Congrats @JAK2TheFuture, @bowman_rl, @rosslevinemd, and colleagues on this important study in #MPNsm published in @CD_AACR. https://t.co/Zn8n6SBvWI